- Remote electrical neuromodulation (REN) is an effective treatment for acute migraine with a favourable safety and tolerability profile.
- It may be an effective alternative for acute migraine treatment with comparable or superior efficacy to commercially available neuromodulation devices.
Why this matters
- REN has the potential to improve patient adherence, migraine management, and the health and quality of life of patients with migraine.
- A randomised, double-blind, sham-controlled, study of 252 patients with migraine who were randomly assigned 1:1 ratio to active (n=126) and sham simulation group (n=126).
- Migraine pain levels recorded at baseline, 2 and 48 hours and most bothersome symptoms (MBS) recorded at baseline and 2 hours post-treatment.
- Primary outcome: proportion of patients achieving pain relief at 2 hours post-treatment.
- Secondary outcome: pain-free, MBS relief, pain and MBS relief, and MBS freedom at 2 hours post-treatment.
- Funding: None disclosed.
- In modified-to-intention treat analysis (n=202), higher proportion of patients in active vs sham group at 2 hours post-treatment achieved:
- pain relief (66.7% vs 38.8%; P<.0001>
- pain-free relief (37.4% vs 18.4%; P=.003)
- MBS relief (46.3% vs 22.2%; P=.0008)
- pain and MBS relief (40.0% vs 15.2%; P=.0004)
- Low rate of severe baseline pain intensity and high rate of mild pain intensity.